DAR-0100A

Phase 2Small molecule

LLarry J. Siever

DAR-0100A is one of 4 small molecule programs targeting Schizotypal Personality Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Schizotypal Personality DisorderActive, not recruiting

Schizotypal Personality DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Schizotypal Personality Disorder

#DrugCompanyPhaseTrials

Intuniv

PPromius Pharma, LLC

Approved

1 2

Risperdal

WWim Janssens

Phase 1

2 3

Permax

VValeant Pharmaceuticals

Preclinical

1 4

DAR-0100A

LLarry J. Siever

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizotypal Personality Disorder1 trial

Clinical Testing of a D1 Agonist for Cognitive Enhancement in Schizotypal Personality Disorder

Unknown status·LLarry J. Siever·Phase 2·NCT01466205·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DAR-0100A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DAR-0100A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DAR-0100A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Larry J. Siever company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLarry J. Siever

DAR-0100A

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizotypal Personality Disorder1 trial

References

Drug Info

Quick Facts

Related News